Esperite NV (ESP):企業の財務・戦略的SWOT分析

◆英語タイトル:Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12806
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Esperite NV (ESP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Esperite NV (Esperite) is a regenerative and precision medicine company. It collects, processes and stores human adult stem cells obtained from umbilical cord blood and cord tissue. Esperite offers a diagnostic system built on the Next Generation Sequencing technology (NGS) that enables laboratories for performing with bioinformatics-based genetic analysis. The company operates a research and development division, the Cell Factory, which is involved in developing advanced cell therapy medicinal products and new therapies in the field of regenerative medicine. The company works in partnership with pharmaceutical and biotechnology companies to advance the development of its products and services. Esperite is headquartred in Amsterdam, the Netherlands.

Esperite NV Key Recent Developments

Nov 23,2018: ESPERITE : financial results for 2017 are published
Nov 06,2018: Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.
Sep 13,2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva
Jun 19,2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies
Jun 11,2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Esperite NV – Key Facts 6
Esperite NV – Key Employees 7
Esperite NV – Key Employee Biographies 8
Esperite NV – Major Products and Services 9
Esperite NV – History 10
Esperite NV – Company Statement 13
Esperite NV – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 17
Company Overview 17
Esperite NV – Business Description 18
Business Segment: Genoma 18
Overview 18
Performance 18
Business Segment: Holding 18
Overview 18
Performance 18
Business Segment: Other 18
Overview 18
Performance 18
Business Segment: Stem Cell 18
Overview 18
Performance 19
Business Segment: The Cell Factory 19
Overview 19
Performance 19
Esperite NV – SWOT Analysis 20
SWOT Analysis – Overview 20
Esperite NV – Strengths 20
Esperite NV – Weaknesses 21
Esperite NV – Opportunities 22
Esperite NV – Threats 23
Esperite NV – Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios – Capital Market Ratios 25
Financial Ratios – Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Esperite NV, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Nov 23, 2018: ESPERITE : financial results for 2017 are published 34
Sep 13, 2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva 41
Jun 19, 2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies 42
Jun 11, 2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding 43
Mar 29, 2018: Esperite, The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases 44
Jan 10, 2018: ESPERITE transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs 46
Oct 09, 2017: Esperite with CryoSave enters the Ukrainian market and fosters its leadership position in Europe 47
Oct 02, 2017: ESPERITE publishes its half-year report 48
May 31, 2017: ESPERITE Q1 consolidated revenue higher compared to budget 49
May 23, 2017: Esperite Financial Results For 2016 Published 50
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Esperite NV, Key Facts 6
Esperite NV, Key Employees 7
Esperite NV, Key Employee Biographies 8
Esperite NV, Major Products and Services 9
Esperite NV, History 10
Esperite NV, Subsidiaries 15
Esperite NV, Key Competitors 24
Esperite NV, Ratios based on current share price 25
Esperite NV, Annual Ratios 26
Esperite NV, Annual Ratios (Cont...1) 27
Esperite NV, Interim Ratios 29
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Esperite NV, Recent Deals Summary 33
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54

List of Figures
Esperite NV, Performance Chart (2013 - 2017) 28
Esperite NV, Ratio Charts 30
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

★海外企業調査レポート[Esperite NV (ESP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tetherex Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Tetherex Pharmaceuticals Corp (Tetherex Pharmaceuticals) is a clinical-stage biopharmaceutical company which develops novel medicines for the treatment of inflammation, thrombosis and tumor metastasis. Its lead pipeline product candidate SelK2, a humanized monoclonal antibody targets a cell …
  • XOMA Corp (XOMA):製薬・医療:M&Aディール及び事業提携情報
    Summary XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358 …
  • Elmet Technologies, Inc.:企業の戦略・SWOT・財務情報
    Elmet Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Elmet Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The E. W. Scripps Company (SSP):企業の財務・戦略的SWOT分析
    The E. W. Scripps Company (SSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Inivata Ltd:製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a clinical cancer genomics company that utilizes the precision of circulating tumor DNA analysis to improve personalized healthcare in oncology. The company uses liquid biopsy platform, to identify and characterize ctDNA through a non-invasive blood test. Its liquid …
  • Wilbur-Ellis Holdings Inc:企業の戦略的SWOT分析
    Wilbur-Ellis Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Aston Martin Lagonda Global Holdings Plc (AML):企業の財務・戦略的SWOT分析
    Aston Martin Lagonda Global Holdings Plc (AML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Zotefoams plc (ZTF):企業の財務・戦略的SWOT分析
    Summary Zotefoams plc (Zotefoams) is a chemical manufacturer that markets cross-linked block foams. The company offers products such as microzote, zotek F, zotek N, T tubes, plastazote, evazote, zotek peba foam, supazote, and others. It offers services such as manufacturing and distribution services …
  • Emlin Cosmetics :企業の戦略・SWOT・財務情報
    Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report Summary Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • JinkoSolar Holding Co Ltd (JKS):電力:M&Aディール及び事業提携情報
    Summary JinkoSolar Holding Co Ltd (JinkoSolar) is a manufacturer of solar products. The company is involved in manufacturing and marketing of solar power products such as silicon ingots, silicon wafers, solar modules, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. …
  • Actinium Pharmaceuticals Inc (ATNM):企業の財務・戦略的SWOT分析
    Summary Actinium Pharmaceuticals Inc (Actinium), formerly Cactus Ventures Inc, is a biopharmaceutical company. It develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab- …
  • Green Cross LabCell Corp (144510):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross LabCell Corp (GCLabCell), a subsidiary of GC Pharma, is a biotechnology company that offers biopharmaceuticals. The company’s products include specialty medicines, blood products and vaccines, generic drugs, parenteral products, and genetically-modified hemophilia A drug Greenjun …
  • Alphabet Inc:企業の戦略・SWOT・財務情報
    Alphabet Inc - Strategy, SWOT and Corporate Finance Report Summary Alphabet Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cerner Corp (CERN):企業の財務・戦略的SWOT分析
    Cerner Corp (CERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Broadridge Financial Solutions, Inc.:戦略・SWOT・企業財務分析
    Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • BASF Corp-エネルギー分野:企業M&A・提携分析
    Summary BASF Corp (BASF), a subsidiary of BASF SE, is a chemical manufacturing company. Its product portfolio includes petrochemicals, monomers, intermediates, dispersions and pigments, care chemicals, nutrition and health products, paper chemicals, performance chemicals, catalysts, construction che …
  • Helm AG:戦略・SWOT・企業財務分析
    Helm AG - Strategy, SWOT and Corporate Finance Report Summary Helm AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Ten Network Holdings Ltd:企業の戦略的SWOT分析
    Ten Network Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • CivaTech Oncology Inc:医療機器:M&Aディール及び事業提携情報
    Summary CivaTech Oncology Inc (CivaTech) is a medical device company that provides radiation therapy solutions. The company develops polymer based low dose rate (LDR) brachytherapy devices for the treatment of cancer. Its product portfolio includes CivaString, a radiation therapy device to treat sol …
  • Ageas NV:企業の戦略・SWOT・財務情報
    Ageas NV - Strategy, SWOT and Corporate Finance Report Summary Ageas NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆